Shares of Oklo surged 16.2% to $22.32 after the advanced nuclear startup reported third-quarter results that cleared a low bar on both earnings and revenue. The company posted a loss of $0.22 per share, narrower than the $0.27 analysts expected.
Revenue hit $1.86 million, nearly doubling the $1.01 million consensus estimate. The beat reverses part of the prior session's 13.2% plunge, but the stock remains deep underwater — down roughly 73% since the start of the year and more than 80% off its 52-week high of $120.95.
• The Beat Looks Big in Percentage Terms, Tiny in Dollar Terms. Revenue of $1.86 million is meaningful only relative to expectations that were close to zero a few quarters ago. A year earlier, Oklo had zero revenue. The company is still pre-commercial — it develops next-generation small modular reactors, with its flagship compact fast reactor designed to power data centers — so these early dollars likely come from government contracts and its radioisotope business, not power sales. The narrower loss matters for cash preservation, but doesn't change the fundamental picture: the company continues to incur "significant operating losses," recording a $33.1 million net loss and $51.2 million operating loss in Q1 alone.
• Government Funding and a Supply-Chain Deal Signal Progress, Not Profit. Alongside earnings, Oklo announced two strategic moves. It won a $6.84 million ARPA-E award under the FORGE program targeting metallic fuel for fast reactors. It also signed a manufacturing agreement with U.S. Forged Rings to reserve domestic capacity for large reactor components in North Carolina, with initial deliveries beginning in 2030. Both signal long-term commitment, but neither generates near-term revenue.
• A Huge Cash Pile Buys Time, but Dilution Has Been the Price. Oklo ended Q2 with roughly $3.0 billion in cash and marketable securities, having raised $1.9 billion via at-the-market equity sales in 2026 — a massive dilution that partly explains the stock's collapse. The current market cap sits around $3.6–4.1 billion , meaning investors are valuing the business itself at barely a premium to its cash.
• Wall Street Is Cautiously Bullish but Targets Have Plummeted. Analysts maintain a Moderate Buy consensus with price targets implying over 200% upside , yet those targets have been slashed repeatedly — Truist cut to $31, Barclays and Piper Sandler also lowered targets in recent weeks. Until Oklo delivers commercial power — targeted for late 2027 — the stock trades on hope, not earnings.